SHERBROOKE and MONTREAL, QC, Jan. 15, 2015 /CNW Telbec/ - Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the discovery and development of novel drug candidates based on proprietary macrocyclic chemistry and the Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR) along with Université de Montréal and its Institute for Research in Immunology and Cancer (IRIC) announced today the signing of a collaborative research agreement. The collaboration intends to utilize Cyclenium's proprietary QUEST Library™ of next generation macrocyclic molecules and associated hit-to-lead optimization expertise in concert with IRIC's state-of the-art capabilities in biological target identification, characterization and screening, as well as medicinal chemistry. The objective of the collaboration is to discover and develop new drug candidates in cutting-edge target areas for the treatment of cancer and immunological disorders.
"We are delighted to have forged this collaboration with IRICoR and the team of leading investigators at IRIC in two of our therapeutic focus areas," stated Helmut Thomas, Ph.D., President & Chief Executive Officer of Cyclenium. "Combining IRIC's exquisite research expertise in the understanding of novel pharmacological targets with our CMRT™ drug discovery technology and our joint experience in the medicinal application of macrocyclic compounds and proven development success in the macrocycle arena offers superb potential for success in the search for new pharmaceuticals in oncology and immunology indications."
"We are extremely pleased to be working with Cyclenium," said Michel Bouvier, Chief Executive Officer of both IRIC and IRICoR. "We clearly see multiple areas of synergy between IRIC's drug discovery, screening, and medicinal chemistry expertise with Cyclenium's leadership position in macrocycle-based drug development."
About Cyclenium Pharma Inc.
About the Institute for Research in Immunology and Cancer
About the Institute for Research in Immunology and Cancer — Commercialization of Research
About the Université de Montréal
SOURCE Cyclenium Pharma Inc.
Contacts: Helmut Thomas, Ph.D., President & Chief Executive Officer, Cyclenium Pharma Inc., Telephone: 819-571-4296, [email protected]; Steven J. Klein, Ph.D, Vice-President, Business Development, Institute for Research in Immunology and Cancer -- Commercialization of Research Telephone: 514-343-6647, [email protected]
Share this article